Quarterly report · Q2
2934.TEDINET S100SM1Y
Period2023-06-01 → 2023-11-30
Filed2024-01-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.0bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥16.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.1bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Operating income | −¥221m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Operating income | −¥389m | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Ordinary income | −¥232m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥403m | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Profit before tax | −¥233m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Profit before tax | −¥403m | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥287m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥354m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥284m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Net income | −¥321m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Total assets | ¥7.4bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥7.2bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥7.9bn | at 2022-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.2bn | at 2023-11-30 | Cons. | Liabilities |
| Total liabilities | ¥4.5bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.1bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.3bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥971m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥594m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥300m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥800m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥933m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-59.33 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-51.91 | 2023-09-01 → 2023-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-410.6 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-77.42 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-48.4 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.1% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.2% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥290m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.4bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.3bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥114m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥19m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥958,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥44m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥8.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥8.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥115m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥69m |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2022-11-30 | −¥84m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2022-11-30 | −¥84m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-11-30 | −¥277m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥3.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥2.9bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥84m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥55m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥248m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥4.2bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥4.2bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥181,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | −¥414m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2022-11-30 | ¥9.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2022-11-30 | ¥9.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥84m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2022-11-30 | −¥112m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 505
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of investment securities inv cf | CurrentYTDDuration | － | JPY |
| Payments of loans receivable inv cf | Prior1YTDDuration | -32000000 | JPY |
| Payments of loans receivable inv cf | CurrentYTDDuration | -94000000 | JPY |
| Payments for lease and guarantee deposits inv cf | Prior1YTDDuration | -13376000 | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYTDDuration | -53332000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | Prior1YTDDuration | 1759000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | CurrentYTDDuration | 1986000 | JPY |
| Other net inv cf | Prior1YTDDuration | -888000 | JPY |
| Other net inv cf | CurrentYTDDuration | 629000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -800326000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -300338000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 147498000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | -109098000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 1100000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 722000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -126175000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -332566000 | JPY |
| Redemption of bonds fin cf | Prior1YTDDuration | -33000000 | JPY |
| Redemption of bonds fin cf | CurrentYTDDuration | -33000000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1YTDDuration | 175181000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYTDDuration | 687486000 | JPY |
| Other net fin cf | Prior1YTDDuration | 2505000 | JPY |
| Other net fin cf | CurrentYTDDuration | -1636000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 1266010000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 933186000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -128072000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -338151000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 2968654000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1588360000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 2840582000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 1250209000 | JPY |
| Ec advertising expenses sga | Prior1YTDDuration | 1864484000 | JPY |
| Ec advertising expenses sga | CurrentYTDDuration | 1894576000 | JPY |
| Depreciation sga | Prior1YTDDuration | 7774000 | JPY |
| Depreciation sga | CurrentYTDDuration | 17605000 | JPY |
| Amortization of goodwill sga | Prior1YTDDuration | 82037000 | JPY |
| Amortization of goodwill sga | CurrentYTDDuration | 102156000 | JPY |
| Amortization of customer related assets | Prior1YTDDuration | 44161000 | JPY |
| Amortization of customer related assets | CurrentYTDDuration | 51935000 | JPY |
| Provision for bonuses selling expenses | Prior1YTDDuration | 29813000 | JPY |
| Provision for bonuses selling expenses | CurrentYTDDuration | 21753000 | JPY |
| Provision for point card certificates | Prior1YTDDuration | 10532000 | JPY |
| Provision for point card certificates | CurrentYTDDuration | -11601000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 4169711000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33800-000HealthcareSalesBusinessReportableSegmentMember | 2019833000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 2914363000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 9103908000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 9103908000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 181000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |